



(51) International Patent Classification:

A61K 9/16 (2006.01) *B01J 13/08* (2006.01)
A61K 9/50 (2006.01) *A61K 31/519* (2006.01)
A61K 9/107 (2006.01) *A61P 35/00* (2006.01)
B01J 13/04 (2006.01)

(21) International Application Number:

PCT/US2022/070910

(22) International Filing Date:

02 March 2022 (02.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/156,020 03 March 2021 (03.03.2021) US

(71) Applicant: **OAKWOOD LABORATORIES, LLC**
[US/US]; 7670 First Place, Suite A, Oakwood Village, Ohio
44146 (US).

(72) Inventors: **GILTNER, Michaela**; 2525 Londonderry Dr.,
Akron, Ohio 44333 (US). **GALASKA, Rachel**; 7670
First Place, Suite A, Oakwood Village, Ohio 44146 (US).
RICHEY, Tracy; 1086 Munroe Falls Kent Road, Kent,


Ohio 44240 (US). **SMITH, Mark**; 7670 First Place, Suite
A, Oakwood Village, Ohio 44146 (US).

(74) Agent: **CHOU, Chia Yun** et al.; 41 South High Street, Suite
2600, Columbus, Ohio 44114 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: MICROSPHERE FORMULATIONS COMPRISING BTK INHIBITORS AND METHODS FOR MAKING AND USING
THE SAME



(57) Abstract: Extended-release microsphere formulations comprising a BTK inhibitor are provided. In one aspect, the microsphere formulations are characterized in that the BTK inhibitor is released in vivo in humans over a period of from about 7 to about 28 days. Methods for making and using the formulations are also provided.

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*